Internal Reference Number: FOI_8584
Date Request Received: 11/04/2025 00:00:00
Date Request Replied To: 08/07/2025 00:00:00
This response was sent via: By Email
Request Summary: Request On Asthma
Request Category: Researcher
| Question Number 1: How many patients have been treated (for any condition) in the last 4 months with: • Benralizumab • Dupilumab • Omalizumab • Reslizumab • Mepolizumab • Tezepelumab | |
| Answer To Question 1: Q1 all zero apart from Dupilumab 30 Omalizumab 18 | |
| Question Number 2: Of the patients treated in the last 4 months with any of the above products, please provide the number of patients by the following age-groups: • Age 6-11 • Age 12-17 • Age 18 and above | |
| Answer To Question 2: All patients 18 and above | |
| Question Number 3: How many patients have been treated in the last 4 months by the Respiratory Medicine department ONLY with: • Dupilumab • Omalizumab | |
| Answer To Question 3: Q 3 Dupilumab 0 Omalizumab 8 | |
| Question Number 4: How many patients have been diagnosed with BOTH chronic sinusitis (ICD-10 code J32) AND nasal polyps (ICD-10 code J33) in the past year? Of these patients, how many have been treated in the last 4 months with: • Benralizumab • Dupilumab • Omalizumab • Reslizumab • Mepolizumab • Tezepelumab | |
| Answer To Question 4: 0 patients diagnosed with both ICD codes were treated in last 4 months with any drug listed. | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
